Početna › Rak žučnog sustava
Kliničke studije za Rak žučnog sustava koje traže sudionike u SAD-u
40 studija za Rak žučnog sustava traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX18 studija
- Los Angeles, CA11 studija
- Boston, MA11 studija
- New York City, NY10 studija
- Nashville, TN9 studija
- San Antonio, TX8 studija
- Baltimore, MD8 studija
- Washington, DC7 studija
- Arlington, VA7 studija
- Pittsburgh, PA7 studija
- Baldwin Park, CA6 studija
- Cleveland, OH6 studija
- Dallas, TX6 studija
- Columbus, OH6 studija
- Madison, WI6 studija
- Philadelphia, PA6 studija
- Detroit, MI5 studija
- Louisville, KY5 studija
- Tampa, FL5 studija
- Miami, FL5 studija
- Orange, CA4 studija
- Seattle, WA4 studija
- Aurora, CO4 studija
- Queens, NY4 studija
- Orlando, FL4 studija
- Buffalo, NY3 studija
- Edison, NJ3 studija
- Santa Monica, CA3 studija
- Salt Lake City, UT3 studija
- St. Louis, MO3 studija
- San Diego, CA3 studija
- Grand Rapids, MI3 studija
- Chicago, IL3 studija
- Tucson, AZ3 studija
- Providence, RI3 studija
- Denver, CO3 studija
- Portland, OR3 studija
- Birmingham, AL3 studija
Po državama
- Alabama3 studija
- Arizona4 studija
- Colorado7 studija
- Connecticut3 studija
- Distrikt Columbia4 studija
- Florida14 studija
- Georgia4 studija
- Illinois5 studija
- Kalifornija20 studija
- Kentucky6 studija
- Maryland11 studija
- Massachusetts11 studija
- Michigan9 studija
- Minnesota5 studija
- Missouri4 studija
- New Jersey5 studija
- New York15 studija
- Ohio10 studija
- Oregon3 studija
- Pennsylvania10 studija
- Rhode Island3 studija
- Tennessee10 studija
- Texas23 studija
- Utah4 studija
- Virginia9 studija
- Washington5 studija
- Wisconsin6 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
U tijeku regrutacijaOpažajna studija
Od 2 do 100 godina · Oba spola · Ažurirano 2. lis 2026. · NCT01950572A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06428409Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
U tijeku regrutacijaFaza 2
Od 18 do 130 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT05489211Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
U tijeku regrutacijaFaza 2
Od 19 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07146646Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06282575SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT07812805Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT06293898CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06548412AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT07038343Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06084481Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 do 99 godina · Oba spola · Ažurirano 24. kol 2026. · NCT05517811A Phase 1 Study of LNCB74 in Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 21. kol 2026. · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 19. kol 2026. · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT06330064D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. srp 2026. · NCT06622057A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
U tijeku regrutacijaFaza 2
Od 8 godina i više · Oba spola · Ažurirano 27. srp 2026. · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT07458347Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.